SDIX is a wholly owned subsidiary
of OriGene Technologies, specializing in high quality, large-scale GMP antibody
production. For over 20 years,
SDIX has been a leading immuno-solutions company, developing results-oriented
and innovative antibody-based solutions that enable customers to meet high
performance research, diagnostic and commercialization objectives.
The OriGene/SDIX antibody collection includes over
10,000 antibodies with options for large scale GMP production in support of
diagnostic reagent manufacturing.
Products include critical reagents such as Strep A, cTnI, CRP, Apo A1,
ApoB, Micro-albumin and Calibrators. For IHC applications, UltraMAB antibodies
are the only class of antibodies validated for mono-specificity. SDIX also
provides both polyclonal and monoclonal antibody development and production
services, including long term supply of monoclonal antibodies for IVD and drug
development applications as well as goat, sheep and rabbit polyclonal
antibodies. In the life science
market, SDIX’s technology and capabilities are being used to help discover
disease mechanisms, facilitate development of new drugs, and provide antibodies
and assays utilized in the diagnosis of disease.
SDIX is proud to have earned a number of certificates which shows our dedication to having a quality and respected operations.
SDIX's News & Media will help you answer your questions about our latest Press Releases, Product News, Upcoming Events and Publications.
Publications from SDIX authors and about our products and services.
Find out if SDIX will be exhibiting at the shows you'll be attending.
A brief history of SDIX -- from Strategic Diagnostics (SDI) to SDIX.